ارتباط سطح سرمی هورمون آنتی‌مولرین با کیفیت تخمک‌ها در سیکل‌های لقاح آزمایشگاهی

نوع مقاله : اصیل پژوهشی

نویسندگان

1 پزشک عمومی، دانشکده پزشکی، دانشگاه علوم پزشکی زاهدان، زاهدان، ایران.

2 استادیار گروه پزشکی اجتماعی، دانشکده پزشکی، دانشگاه علوم پزشکی زاهدان، زاهدان، ایران.

3 دانشیار گروه زنان و مامایی، مرکز تحقیقات بیماری‌های عفونی و گرمسیری، دانشکده پزشکی، دانشگاه علوم پزشکی زاهدان، زاهدان، ایران.

4 متخصص زنان و زایمان، دانشکده پزشکی، دانشگاه علوم پزشکی ایران، تهران، ایران.

چکیده

مقدمه: سطح سرمی هورمون آنتی‌مولرین (AMH)، یک ابزار قدرتمند برای پیش‌بینی پاسخ تخمدان است که نه تنها اندازه فولیکول اولیه، بلکه کیفیت تخمک را نیز منعکس می‌کند. مطالعه حاضر با هدف تعیین ارتباط بین سطح سرمی AMH و کیفیت تخمک‌های حاصل از سیکل‌های IVF در مرکز نازایی زاهدان انجام شد.
روش‌کار: این مطالعه مقطعی (توصیفی- تحلیلی) در سال 97-1396 بر روی 108 زن نابارور که کاندید انجام IVF بودند، در شهر زاهدان انجام شد. بیماران به‌روش سرشماری انتخاب و وارد مطالعه شدند. اطلاعات لازم از قبیل سن، کیفیت تخمک‌ها و سطح سرمی AMH استخراج و در فرم اطلاعاتی هر بیمار ثبت شد. تجزیه و تحلیل داده‌ها با استفاده از نرم‌افزار آماری SPSS (نسخه 19) و آزمون‌های کای دو و آنووا انجام شد. میزان p کمتر از 05/0 معنی‌دار در نظر گرفته شد.
یافته‌ها: میانگین سطح سرمی AMH بیماران 26/3±81/3 نانوگرم بر میلی‌لیتر بود. 87 بیمار (6/80%) تخمک با کیفیت A، 80 بیمار (1/74%) تخمک با کیفیت B، 34 بیمار (5/31%) تخمک با کیفیت C و 1 بیمار (9/0%) تخمک با کیفیت D داشتند. میانگین سنی با سطح سرمی AMH و کیفیت تخمک‌ها ارتباط معناداری نداشت (05/0>p).
نتیجه‌گیری: سطح AMH با کیفیت تخمک‌ها در سیکل‌های IVF ارتباط داشت، در حالی‌که سن با سطح AMH و کیفیت تخمک‌ها ارتباط نداشت. بنابراین سطح AMH می‌تواند به‌عنوان یک نشانگر برای کیفیت تخمک‌ها در سیکل‌های IVF مورد استفاده قرار گیرد.

کلیدواژه‌ها

عنوان مقاله [English]

The Relationship between Serum Anti Müllerian Hormone Level and Oocyte quality in In Vitro Fertilization Cycles

نویسندگان [English]

  • Fatemeh Keikha 1
  • Saeedeh Sarhadi 2
  • Farahnaz Farzaneh 3
  • Maryam Zamani 4
1 General Practitioner, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
2 Assistant Professor, Department of Community Medicine, Faculty of Medicine, Zahedan University of Medical Science, Zahedan, Iran.
3 Associate professor, Department of Obstetrics and Gynecology, Infectious disease and Tropical Medicine Research Center, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.
4 Gynecologist, Faculty of Medicine, Iran University of Medical Science, Tehran, Iran.
چکیده [English]

Introduction: The serum level of Anti Müllerian hormone (AMH) is a powerful test for predicting ovarian response that reflects not only the size of the primary follicle but also the quality of the oocytes. This study was conducted aimed to determine the relationship between serum AMH levels and the quality of oocytes obtained from IVF cycles in patients using IVF in Zahedan infertility center.
Methods: This descriptive-analytical study was performed in 2017-2018 on 108 infertile women who were candidates for IVF in Zahedan. Patients were selected by census and entered the study. Patients' files were extracted and the necessary information such as age, oocytes quality and serum AMH levels were extracted and recorded in the patient's information form. Data were analyzed by SPSS software (version 19) and Chi-Square test and ANOVA. P< 0.05 was considered statistically significant.
Results: The mean serum AMH level of patients was 3.81 ± 3.26 ng/ml. 87 patients (80.6%) had oocyte quality (A), 80 patients (74.1%) had B quality, 34 patients (31.5%) had C quality and one patient (0.9%) had D quality. The mean age was not significantly associated with serum AMH levels and oocytes quality (P> 0.05).
Conclusions: AMH levels are associated with oocyte quality in IVF cycles, while age was not associated with AMH levels and oocyte quality. Therefore, AMH levels are an indicator of the quality of oocyte in IVF cycles.

کلیدواژه‌ها [English]

  • AMH
  • IVF
  • Oocyte quality

مراجع

  1. Gelbaya TA, Potdar N, Jeve YB, Nardo LG. Definition and epidemiology of unexplained infertility. Obstetrical & gynecological survey 2014; 69(2):109-15.
  2. Hilbert SM, Gunderson S. Complications of assisted reproductive technology. Emergency Medicine Clinics 2019; 37(2):239-49.
  3. Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility. Journal of assisted reproduction and genetics 2020; 37(1):89-100.
  4. Victoria M, Labrosse J, Krief F, Cédrin-Durnerin I, Comtet M, Grynberg M. Anti Müllerian Hormone: more than a biomarker of female reproductive function. Journal of gynecology obstetrics and human reproduction 2019; 48(1):19-24.
  5. Pepinsky RB, Sinclair LK, Chow EP, Mattaliano RJ, Manganaro TF, Donahoe PK, et al. Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. Journal of Biological Chemistry 1988; 263(35):18961-4.
  6. Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reproductive biomedicine online 2015; 31(4):486-96.
  7. Cui L, Lin Y, Lin J, Wang F. AMH-based ovarian stimulation versus conventional ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis. Archives of gynecology and obstetrics 2020; 301(4):913-22.
  8. Sefrioui O, Madkour A, Aboulmaouahib S, Kaarouch I, Louanjli N. Women with extreme low AMH values could have in vitro fertilization success. Gynecological Endocrinology 2019; 35(2):170-3.
  9. Lehmann P, Vélez MP, Saumet J, Lapensée L, Jamal W, Bissonnette F, et al. Anti-Müllerian hormone (AMH): a reliable biomarker of oocyte quality in IVF. Journal of assisted reproduction and genetics 2014; 31(4):493-8.
  10. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Human reproduction 2007; 22(3):766-71.
  11. Nezamdoust S, Farzaneh F. Comparison of the effect of trigger of ovulation with HCG and HCG plus oxytocin on the biochemical pregnancy. Iran J Obstet Gynecol Infertil 2020; 22(12):19-23.
  12. Omani-Samani R, Sepidarkish M, Safiri S, Esmailzadeh A, Vesali S, Farzaneh F, et al. Impact of gestational weight gain on cesarean delivery risk, perinatal birth weight and gestational age in women with normal pre-pregnancy BMI. The Journal of Obstetrics and Gynecology of India 2018; 68(4):258-63.
  13. Farzaneh F, Saravani M, Esmailpoor M, Mokhtari M, Teimoori B, Rezaei M, et al. Association of HOTAIR gene polymorphisms and haplotypes with uterine leiomyoma susceptibility in southeast of Iran. Molecular biology reports 2019; 46(4):4271-7.
  14. Farzaneh F, Afshar F. Comparison of ovulation induction with letrozole plus dexamethasone and letrozole alone in infertile women with polycystic ovarian disease: An RCT. International Journal of Reproductive BioMedicine 2020; 18(4):307-10.
  15. Behnoud N, Rezaei R, Estorm E, Farzaneh F. The relationship between endometrial thickness and endometrial pattern with pregnancy rate based on positive serum beta-human chorionic gonadotropin. International Journal of Womens Health and Reproduction Sciences 2019; 7(3):400-3.
  16. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility and sterility 2002; 77(3):468-71.
  17. Pellestor F, Andréo B, Arnal F, Humeau C, Demaille J. Maternal aging and chromosomal abnormalities: new data drawn from in vitro unfertilized human oocytes. Human genetics 2003; 112(2):195-203.
  18. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Human Reproduction 2006; 21(8):2022-6.
  19. Arabzadeh S, Hossein G, Rashidi BH, Hosseini MA, Zeraati H. Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome. Annals of Saudi medicine 2010; 30(6):442-7.
  20. Alanazi H, Bushaqer N, Ayyoub H, Dayoub N, Hassan S. Antimullerian hormone (AMH) level and IVF/ICSI cycle outcome in expected poor responders. Middle East Fertility Society Journal 2018; 23(3):246-50.
  21. Erfanian Ahmadpour M, Keramati Jamal M, Khalilifar H. Investigate the relationship between serum hormone anti-mullerian and results of assisted reproductive technology cycles in infertile patients referred to an Infertility center in 2012 to 2013. Medical Journal of Mashhad University of Medical Sciences 2014; 4(2):1-16. (Persian)
  22. Gomez R, Schorsch M, Hahn T, Henke A, Hoffmann I, Seufert R, et al. The influence of AMH on IVF success. Archives of gynecology and obstetrics 2016; 293(3):667-73.
  23. Asadzadeh N, Chaichian S, Ziadloo M, Bayat SM, Sheikhvatan M. Long-term recurrence of endometriosis in women with subfertility caused by endometriosis: a comparison of the efficacy of surgery and assisted reproductive technology as fertilization treatment approaches. Shiraz E Medical Journal 2021; 22(1):1-6.
مجله زنان، مامایی و نازایی ایران
دوره 24، شماره 13
اسفند 1400
صفحه 35-40

فایل ها

هم رسانی

ارجاع به این مقاله

آمار